Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (381-390 of 404) with videos related to

Pageof 41
Sort By:
Nature Genetics|April 11, 2017
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosisMohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The International Journal on Drug Policy|January 6, 2026
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysisEvan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, et al.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
Immunity|January 16, 2025
A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune diseaseClara Young, Mandeep Singh, Katherine J L Jackson, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
Plos Medicine|September 21, 2011
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyVijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, et al.
Nature Communications|September 16, 2016
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis CKhaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Pageof 41

Showing results (381-390 of 404) with videos related to

Sort By:
Pageof 41
Nature Genetics|April 11, 2017
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosisMohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The International Journal on Drug Policy|January 6, 2026
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysisEvan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, et al.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
Immunity|January 16, 2025
A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune diseaseClara Young, Mandeep Singh, Katherine J L Jackson, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
Plos Medicine|September 21, 2011
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyVijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, et al.
Nature Communications|September 16, 2016
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis CKhaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Pageof 41